See more : Comvita Limited (CVT.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Applied Genetic Technologies Corporation (AGTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Applied Genetic Technologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- The Bank of N.T. Butterfield & Son Limited (NTB) Income Statement Analysis – Financial Results
- Periphas Capital Partnering Corporation (PCPC) Income Statement Analysis – Financial Results
- THK Co., Ltd. (THKLY) Income Statement Analysis – Financial Results
- State Auto Financial Corporation (STFC) Income Statement Analysis – Financial Results
- Orient EuroPharma Co., Ltd. (4120.TWO) Income Statement Analysis – Financial Results
Applied Genetic Technologies Corporation (AGTC)
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 49.52M | 44.40M | 35.78M | 33.18M | 32.18M | 26.22M | 38.86M | 16.53M | 8.50M | 3.13M | 2.35M |
| General & Administrative | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Cost & Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.00K | 0.00 | 0.00 |
| Interest Expense | 2.67M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.00K | 69.00K |
| Depreciation & Amortization | 1.51M | 1.46M | 1.34M | 1.27M | 1.18M | 912.00K | 567.00K | 376.00K | 334.00K | 285.00K | 262.00K |
| EBITDA | -64.76M | -56.97M | -46.94M | -4.35M | -20.05M | 3.72M | -814.00K | -24.53M | -12.56M | -4.51M | -1.59M |
| EBITDA Ratio | -19,925.23% | -11,394.20% | -1,813.05% | -1.58% | -82.91% | 9.42% | -1.72% | -1,017.08% | -1,379.45% | -479.19% | -147.23% |
| Operating Income | -66.27M | -58.45M | -46.94M | -4.35M | -22.38M | 1.90M | -2.09M | -24.53M | -12.56M | -3.59M | -2.06M |
| Operating Income Ratio | -20,390.46% | -11,690.20% | -1,913.66% | -10.43% | -92.55% | 4.82% | -4.41% | -1,042.14% | -1,112.13% | -381.53% | -190.30% |
| Total Other Income/Expenses | -2.58M | -1.39M | 1.18M | 2.46M | 1.18M | 905.00K | 708.00K | 214.00K | -3.35M | -1.40M | 135.00K |
| Income Before Tax | -68.75M | -59.84M | -45.76M | -1.90M | -21.21M | 2.81M | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Income Before Tax Ratio | -21,153.85% | -11,968.20% | -1,865.55% | -4.55% | -87.69% | 7.11% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| Income Tax Expense | 2.67M | -2.11M | 83.00K | 76.00K | 72.00K | 2.40M | 708.00K | 214.00K | -3.35M | -1.21M | 204.00K |
| Net Income | -71.42M | -57.83M | -45.89M | -2.01M | -21.30M | 407.00K | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Net Income Ratio | -21,976.62% | -11,565.80% | -1,870.85% | -4.81% | -88.07% | 1.03% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| EPS | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| EPS Diluted | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| Weighted Avg Shares Out | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.07M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
| Weighted Avg Shares Out (Dil) | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.39M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
Analysts Are Bullish on These Healthcare Stocks: Avid Bioservices (CDMO), Agile Therapeutics (AGRX)
Analysts Offer Insights on Healthcare Companies: Vaxart (VXRT), Enlivex Therapeutics (ENLV) and Capricor Therapeutics (CAPR)
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
Analysts Are Bullish on These Healthcare Stocks: Lineage Cell Therapeutics (LCTX), Menlo Therapeutics (MNLO)
Source: https://incomestatements.info
Category: Stock Reports